The score is driven primarily by strong financial performance (high margins, low leverage, and solid cash conversion) and supportive valuation (low P/E and high dividend yield). This is tempered by mixed/neutral technical signals, including slightly negative MACD and prices sitting near moving averages.
Positive Factors
High Profitability / Margins
Sustained gross (~77%) and net (~22%) margins materially bolster durable earnings power and internal funding capacity. High margins provide structural cushion against reimbursement or cost shocks, support reinvestment and dividends, and improve resilience across economic cycles over the next several quarters.
Negative Factors
Revenue Growth Volatility
Irregular top-line trends, including prior declines and a 2025 rebound, weaken predictability of future sales and cash flow. This volatility complicates capacity planning and raises the risk that recent margin and cash improvements are cyclical rather than structural, challenging durable growth planning.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability / Margins
Sustained gross (~77%) and net (~22%) margins materially bolster durable earnings power and internal funding capacity. High margins provide structural cushion against reimbursement or cost shocks, support reinvestment and dividends, and improve resilience across economic cycles over the next several quarters.
Read all positive factors
Medinex Ltd. (OTX) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$30.27M
Dividend Yield7.3%
Average Volume (3M)102.58K
Price to Earnings (P/E)9.3
Beta (1Y)-0.06
Revenue Growth-2.08%
EPS Growth129.31%
CountrySG
Employees73
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.02
Shares Outstanding134,543,840
10 Day Avg. Volume45,910
30 Day Avg. Volume102,580
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.57
Price to Sales (P/S)2.05
P/FCF Ratio7.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medinex Ltd. Business Overview & Revenue Model
Company Description
Medinex Limited, an investment holding company, provides professional support services to medical clinics in Singapore. It operates through four segments: Medical Support Services, Business Support Services, Pharmaceutical Services, and Medical Se...
Read more
Medinex Ltd. Financial Statement Overview
Summary
Strong overall fundamentals supported by high 2025 margins (gross ~77%, net ~22%), conservative leverage (debt-to-equity ~0.10), and solid cash conversion (operating cash flow ~1.04x net income; free cash flow ~0.99x). The main risk is year-to-year volatility in revenue growth and profitability, making sustainability of the 2025 rebound important.
Income Statement
78
Positive
Balance Sheet
83
Very Positive
Cash Flow
86
Very Positive
Breakdown
Mar 2024
Mar 2023
Mar 2022
Mar 2021
Mar 2021
Income Statement
Total Revenue
12.81M
12.58M
12.97M
11.99M
10.79M
Gross Profit
9.93M
9.68M
9.48M
8.57M
3.31M
EBITDA
3.58M
1.79M
2.88M
4.00M
1.69M
Net Income
2.83M
1.03M
1.70M
2.81M
3.49M
Balance Sheet
Total Assets
20.69M
20.50M
22.59M
22.98M
23.43M
Cash, Cash Equivalents and Short-Term Investments
5.56M
5.17M
4.15M
6.34M
6.73M
Total Debt
1.67M
2.08M
2.34M
3.10M
3.95M
Total Liabilities
3.96M
4.34M
4.81M
5.51M
6.50M
Stockholders Equity
16.72M
16.12M
17.57M
17.25M
16.66M
Cash Flow
Free Cash Flow
3.33M
2.67M
2.83M
2.63M
2.96M
Operating Cash Flow
3.35M
2.70M
3.03M
2.86M
3.04M
Investing Cash Flow
243.45K
1.66M
-2.19M
-16.91K
-2.61M
Financing Cash Flow
-3.20M
-3.33M
-3.02M
-3.16M
748.53K
Medinex Ltd. Technical Analysis
Technical Analysis Sentiment
Positive
Last Price0.24
Price Trends
50DMA
0.23
Negative
100DMA
0.23
Negative
200DMA
0.22
Positive
Market Momentum
MACD
>-0.01
Negative
RSI
53.12
Neutral
STOCH
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:OTX, the sentiment is Positive. The current price of 0.24 is above the 20-day moving average (MA) of 0.23, above the 50-day MA of 0.23, and above the 200-day MA of 0.22, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 53.12 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SG:OTX.
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 24, 2026